Merck reported Q1 adjusted EPS of $2.22, beating analyst expectations Company lowered 2025 profit guidance due to tariffs costing an extra $200 million Keytruda sales grew 4% to $7.2 billion but fell ...

The lawsuit alleges that Merck misrepresented demand for its Gardasil vaccine in China, leading to inflated inventories ... or just someone who bought stock after watching a Gardasil commercial, you ...

The company’s strong commercial ... shipments of its HPV vaccine Gardasil to China until mid-2025 due to weak discretionary spending. Despite these short-term challenges, Merck & Co., Inc ...

A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers caused by the human papillomavirus and one of ...

In a statement, Merck said regulatory agencies have continued to conclude HPV vaccines are safe and effective, as have 30 years of research. Clinical trials have included over 70,000 people with ...

Merck, with a 76.59% gross margin and $63.17 billion in revenue, continues expanding its global vaccine reach. Moreover, Merck announced a $0.81 quarterly dividend and a $10 billion stock buyback ...

"You go online, you do commercials ... pharmaceutical company Merck & Co. over allegations it failed to properly warn patients about risks associated with Gardasil, the vaccine that protects ...

Merck is anchored today by a robust set of commercial products addressing ... advanced renal cell carcinoma in the U.S. In ...

Merck’s stock tumbled 11.8% Tuesday ... after the drug company’s softer-than-expected guidance amid struggles for its HPV vaccine in China overshadowed a quarterly earnings beat.

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come ... Merck would be open to picking up commercial assets as well, he added. The Gardasil move was no doubt ...

Merck’s Q4 sales rose 7% YoY to $15.62B, slightly beating the $15.49B consensus. Adjusted EPS jumped to $1.72, topping estimates of $1.62. Keytruda sales grew 19% YoY to $7.84B, while Gardasil ...